---
title: "Lumos Director Doug Ward Increases On‑Market Shareholding"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297589879.md"
description: "Lumos Diagnostics Holdings Ltd announced that Director Doug Ward increased his on-market shareholding by acquiring 202,131 shares for approximately $21,224. This raises his direct stake to 2,945,131 shares. The transaction signals insider confidence in the company's outlook and ensures compliance with disclosure requirements. Lumos is a medical diagnostics firm focused on point-of-care testing solutions."
datetime: "2026-09-01T03:12:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297589879.md)
  - [en](https://longbridge.com/en/news/297589879.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297589879.md)
generator: "portal-rs"
---

# Lumos Director Doug Ward Increases On‑Market Shareholding

An announcement from Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) is now available.

Lumos Diagnostics has reported a change in the holdings of director Doug Ward, who increased his stake in the company through an on‑market purchase. Ward acquired 202,131 fully paid ordinary shares for approximately $21,224, lifting his direct shareholding to 2,945,131 shares, alongside substantial unlisted options and performance rights, as well as an unchanged indirect holding of 8,348,083 shares.

The transaction underscores continued insider support for Lumos Diagnostics, with Ward’s expanded position potentially viewed as a signal of confidence in the company’s outlook. The update also clarifies the nature of his direct and indirect holdings, aligning registered holdings with disclosure requirements and providing greater transparency for investors and other market stakeholders.

The most recent analyst rating on (AU:LDX) stock is a Buy  
 with a A$0.25 price target.  
 To see the full list of analyst forecasts on Lumos Diagnostics Holdings Ltd. stock,  
 see the AU:LDX Stock Forecast page. 

**More about Lumos Diagnostics Holdings Ltd.**

Lumos Diagnostics Holdings Ltd is a medical diagnostics company focused on developing and supplying rapid point‑of‑care testing solutions. The company operates in the healthcare and life sciences sector, providing diagnostic products and related technologies for clinical and commercial partners.

**Average Trading Volume:** 2,527,187

**Technical Sentiment Signal:** Sell

**Current Market Cap:** A$94.48M

For an in-depth examination of LDX stock, go to TipRanks’ Overview page.

### Related Stocks

- [LDX.AU](https://longbridge.com/en/quote/LDX.AU.md)

## Related News & Research

- [Lumos Director Increases Shareholding and Corrects Prior Holding Record](https://longbridge.com/en/news/284712628.md)
- [Lumos Director Catherine Robson Increases Indirect Shareholding via Purchases and Share Plan](https://longbridge.com/en/news/284856753.md)
- [ScienceSoft Predicts One in Ten US Medical Visits Will Be Virtual by 2030](https://longbridge.com/en/news/298602794.md)
- [REG - EDX Medical Group - Director/PDMR shareholdings in the Company](https://longbridge.com/en/news/298058813.md)
- [Underlying Inflation Hits Lowest Since 2021: Why Markets Bet On Fed Hikes?](https://longbridge.com/en/news/298745975.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**